Moleac
Latest round
- Series A
Last raised
- Apr 2008
Total raised
- $3.5M
Investors
- 1
About Moleac
Moleac is a specialty pharma company which identifies promising traditional Chinese medicines (TCMs) and which develops them as Western medicine (“modernizing” TCMs). Focusing on unmet medical needs, Moleac drives research, development and registration for a pipeline of drugs and devices. Its first product Neuroaid, which helps patients recover from a stroke, is now marketed in more than 30 countries and continues to undergo clinical trials to extend its indications. The company is also implementing further research on identifying underlying mechanisms of actions.
Who invested in Moleac
1 investor across 1 round
See all investors in Moleac
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Apr 3, 2008
Amount
$3.5M
Investors
Questions about Moleac
Who invested in Moleac?
Moleac has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Moleac raised?
Moleac has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Moleac last raise money?
Moleac's most recent round on record is a Series A, in Apr 2008.
What does Moleac do?
Moleac is a specialty pharma company which identifies promising traditional Chinese medicines (TCMs) and which develops them as Western medicine (“modernizing” TCMs).
Where is Moleac headquartered?
Moleac is headquartered in Singapore, Singapore.
Which VCs invest in companies like Moleac?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at Moleac's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series A
Raising like Moleac? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.